Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Myung-Ju Ahn is Professor of Hemato-Oncology in the Department of Medicine at Sungkyunkwan University School of Medicine in Seoul, Korea. She is a member of numerous associations and societies dedicated to cancer research, such as the International Society of Lung Cancer Association, the American Association of Cancer Research, the American Society of Clinical Oncology, the Korean Society of Medical Oncology and the Korean Cancer Study Group, where she is also Chief of the executive committee and chairperson of Lung Cancer Disease Committee. She was a president of the Korean Society of Medical Oncology (2018-2019) and she was a president of the Multidisciplinary Immuno-oncology Study Group (2017-2018). She serves as a board member for the Korean Association of Cancer and the Korean Society of Medical Oncology, Korean Association for Lung Cancer, and Korean Association for Cancer, and also serves on the Editorial board of Journal of Thoracic Oncology.



Professor Ahn received her education from Hanyang University College of Medicine in Seoul, where she earned her medical degree, as well as her doctorate. She completed her residency training in internal medicine at Hanyang University Hospital, and held numerous fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center in New York, USA.




Professor Ahn has authored or co-authored over 250 publications. Her research interests include the development of predictive and prognostic marker in lung cancer in terms of personalized therapy, and her recent research focuses on the early clinical trial for the development of drug discovery and reposition of targeted drugs, as well as the development of NSCLC genome atlas. In recognition of her dedication to cancer research, she has been awarded multiple honours, including the 2003 Best Researcher Award from the Korean Medical Women’s Association, the 2015 Best Researcher Award from the Korean Association of Clinical Oncology, and the 2018 Boryoung Scientific Award from the Korean Cancer Research Foundation.